Table 1.
Patient and tumor characteristics for all patients and patients in oncological follow-up.
| All patients (surgical follow-up) (n = 17) | Oncological follow-up (n = 13) | |
|---|---|---|
| Median age, years (range) | 65 (48–77) | 65 (48–77) |
| Median body mass index, kg/m2 (range) | 28,9 (23,3–32,7) | 24,7 (23,3–32,7) |
| Median PSA at diagnosis, ng/mL (range) | 12 (5,2–38) | 12 (5,9–38) |
| Gleason score, n (%) | ||
| 6 | 1 (6) | 1 (8) |
| 7 (3 + 4) | 5 (29) | 4 (31) |
| 7 (4 + 3) | 3 (18) | 2 (15) |
| 8 | 5 (29) | 4 (31) |
| 9 | 3 (18) | 2 (15) |
| 10 | — | — |
| Clinical tumor stage, n (%) | ||
| T2 | 6 (35) | 5 (38) |
| T3a | 4 (24) | 4 (31) |
| T3b | 3 (18) | 1 (8) |
| T4 | 1 (6) | 1 (8) |
| Unknown | 3 (18) | 2 (15) |
| Primary treatment, n (%) | ||
| Surgery | 14 (82) | 11 (85) |
| Radiotherapy | 2 (12) | 2 (15) |
| High-intensity, focused ultrasound | 1 (6) | — |
| Previous PLND, n (%) | 5 (29) | — |
| Median PSA at SLND, ng/mL (range) | 2,01 (0,24–26,54) | 2,01 (0,69–26,54) |
| Median PSAdt at SLND, months (range) | 5,3 (1,5–46,5) | 5,1 (1,6–19,8) |
| Median follow up, months (range) | 22 (4–60) | 21 (4–60) |
*PSA = prostate specific antigen; PSAdt = PSA doubling time; PLND = pelvic lymph node dissection; SLND = salvage pelvic lymph node dissection.